Timolol treats myopic regression


Timolol is successful in treating myopic regression after LASIK and lasts for at least six months.

Timolol is successful in treating myopic regression after LASIK and lasts for at least six months.

Dr Ahmad Shojaei et al., Department of Ophthalmology, Baghiatalah University of Medical Sciences, Tehran, Iran, compiled a prospective, randomized, parallel-controlled, double-masked clinical trial on 90 eyes with myopic regression after LASIK.

Group one consisted of 45 eyes that received timolol 0.5% eye drops and group two who received artificial tears for six months. The main outcome measure was spherical equivalent (SE) six months postoperatively.

SE improved from −1.48 ± 0.99 D in the timolol group before treatment to −0.88 ± 0.91 D and −0.86 ± 0.93 D six months after treatment and six months after timolol discontinuation.

In the artificial tears group the SE outcomes were −1.57 ± 0.67 D, −1.83 ± 0.76 D, and −1.91 ± 0.70 D, respectively. However, in group one there was a 0.26 D decrease in improvement every four months postoperatively.

To read the abstract please visit the American Journal of Ophthalmology.

Recent Videos
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
© 2024 MJH Life Sciences

All rights reserved.